Atlanta, September 22, 2013 – The American Society for Radiation Oncology (ASTRO) will highlight the recently published Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline during ASTRO's 55th Annual Meeting, September 22-25, 2013, in Atlanta.
The guideline focuses on radiation therapy after prostatectomy for patients with and without evidence of prostate cancer recurrence, and is a joint effort between ASTRO and the American Urological Association (AUA). The 81-page document represents an intensive collaboration among experts in the radiation oncology and urology fields, led by Richard K. Valicenti, MD, MBA, professor and chair of the department of radiation oncology at the University of California Davis Comprehensive Cancer Center in Sacramento, on behalf of ASTRO, and Ian M. Thompson Jr., MD, director of the Cancer Therapy and Research Center at the University of Texas Health Science Center at San Antonio and the Glenda and Gary Woods Distinguished Chair in genitourinary oncology, on behalf of the AUA.
The Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline is a comprehensive review of 324 research articles of English-language publications within the Pubmed, Embase and Cochrane databases, published from January 1, 1990 through December 15, 2012. The guideline is available online free as a PDF document at http://www.redjournal.org and http://www.auanet.org, and was published in the August 1, 2013, print issue of the International Journal of Radiation Oncology • Biology • Physics (Red Journal), the official scientific journal of ASTRO, and in the August 2013 print issue of The Journal of Urology, the official journal of the AUA.
The strategies and approaches recommended were derived from evidence-based and consensus-based processes in the reviewed articles. The systematic review included articles that provided detailed efficacy for patients with detectable and undetectable prostatic specific antigen (PSA) levels, toxicity and quality of life impact, and optimal imaging strategies to determine the appropriateness of radiation therapy use in patients suspected of recurrence. Only studies in which PSA data were provided for 75 percent or more patients were included in the guideline.
The guideline document provides the following clinical principles, recommendations, standards and options: 1) patients who are being considered for management of localized prostate cancer with radical prostatectomy should be informed of the potential for adverse pathologic findings that portend a higher risk of cancer recurrence; 2) patients with adverse pathologic findings including seminal vesicle invasion, positive surgical margins and extraprostatic extension should be informed that adjuvant radiation therapy, compared to radical prostatectomy only, reduces the risk of biochemical (PSA) recurrence, local recurrence and clinical progression of cancer; 3) physicians should offer adjuvant radiation therapy to patients with adverse pathologic findings at the time of prostatectomy, including seminal vesicle invasion, positive surgical margins or extraprostatic extension because of demonstrated reductions in biochemical recurrence, local recurrence and clinical progression; 4) patients should be informed that the development of a PSA recurrence after surgery is associated with a higher risk of development of metastatic prostate cancer or death from the disease; 5) clinicians should define biochemical recurrence as a detectable or rising PSA value after surgery that is ≥ 0.2 ng/ml with a second confirmatory level ≥ 0.2 ng/ml; 6) a restaging evaluation in the patient with a PSA recurrence may be considered; 7) physicians should offer salvage radiation therapy to patients with PSA or local recurrence after radical prostatectomy in whom there is no evidence of distant metastatic disease; 8) patients should be informed that the effectiveness of radiation therapy for PSA recurrence is greatest when given for lower levels of PSA; and 9) patients should be informed of the possible short-term and long-term urinary, bowel and sexual side effects of radiation therapy, as well as the potential benefits of controlling disease recurrence.
In addition to Drs. Valicenti and Thompson, authors of the Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline include Peter C. Albertsen, MD, MS, of the University of Connecticut Health Center; Brian J. Davis, MD, PhD, of the Mayo Clinic; S. Larry Goldenberg, MD, of the Vancouver Prostate Centre at the University of British Columbia; J. Stuart Wolf Jr., MD, of the University of Michigan; Oliver Sartor, MD, of the Tulane University School of Medicine; Eric A. Klein, MD, of the Cleveland Clinic; Carol A. Hahn, MD, of Duke University Medical Center; Jeff M. Michalski, MD, MBA, FASTRO, of the Siteman Cancer Center at the Washington University School of Medicine in St. Louis; Mack Roach, III, MD, of the Helen Diller Family Comprehensive Cancer Center at the University of California, San Francisco; and Martha Faraday, PhD, of Four Oaks Inc.
"This guideline explicitly includes a multitude of significant clinical trial results from more than 20 years of thorough research," said Dr. Valicenti. "There is a critical need for evidence-based standards, recommendations and options to maximize our ultimate goal of increased patient survival and quality of life. This guideline is a compendium of the vast wealth of research available and provides a thorough treatment template for us to consider for prostate cancer patients after a radical prostatectomy."
"The work of the AUA and ASTRO staff, as well as our exceptional guideline panelists, was outstanding," said Dr. Thompson. "This guideline provides a very practical approach for the clinician to help guide in patient decision-making that will result in the very best patient outcomes."
The Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline is jointly copyrighted by ASTRO and the AUA. It will serve as a new, living manifesto of both specialties' dedication to optimal patient care and outcomes and will be updated regularly.
"Many thanks to the dedicated efforts of Drs. Valicenti and Thompson for leading the extraordinary effort to issue this important document from both specialty organizations," said Michael L. Steinberg, MD, FASTRO, chairman of ASTRO's Board of Directors. "The Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline is an essential tool for every practice as they determine the best treatment plan for prostate cancer patients after prostatectomy."
"We are very pleased that ASTRO and AUA came together to create this important document," said Dr. Wolf, chairman of the AUA's Practice Guidelines Committee. "By collaborating and cooperating, we have built on the strengths of both specialties to improve patient care."
The Adjuvant and Salvage Radiotherapy After Prostatectomy: ASTRO/AUA Guideline will be presented during the ASTRO Guidelines Highlight session at ASTRO's 55th Annual Meeting at 3:10 p.m. on Monday, September 23, 2013. Dr. Valicenti will present the guideline, and Dr. Hahn will serve as the discussant. The session will be moderated by Lynn D. Wilson, MD, MPH, FASTRO, ASTRO Annual Meeting Scientific Committee chairman and vice-chairman of the department of therapeutic radiology at Yale School of Medicine in New Haven, Conn., and Benjamin Movsas, MD, FASTRO, ASTRO Annual Meeting Scientific Committee vice-chairman and chairman of the department of radiation oncology at Henry Ford Health System in Detroit.
To speak with Dr. Valicenti or ASTRO leadership, please contact Michelle Kirkwood, September 22-25, 2013, in the ASTRO Press Office at the Georgia World Congress Center in Atlanta at 404-222-5303 or 404-222-5304, or email firstname.lastname@example.org. The complete text of the guideline is available with open access in the Red Journal.
ASTRO's 55th Annual Meeting, held in Atlanta, September 22-25, 2013, is the premier scientific meeting in radiation oncology and brings together more than 11,000 attendees including oncologists from all disciplines, medical physicists, dosimetrists, radiation therapists, radiation oncology nurses and nurse practitioners, biologists, physician assistants, practice administrators, industry representatives and other health care professionals from around the world. The theme of the 2013 meeting is "Patients: Hope • Guide • Heal" and will focus on patient-centered care and the importance of the physician's role in improving patient-reported outcomes and the quality and safety of patient care. The four-day scientific meeting includes presentation of four plenary papers, 363 oral presentations, 1,460 posters and 144 digital posters in 70 educational sessions and scientific panels for 19 disease sites/tracks. Keynote and featured speakers include: William B. Munier, director of the Center for Quality Improvement and Patient Safety at the Agency for Healthcare Research and Quality; Darrell G. Kirch, MD, president and CEO of the Association of American Medical Colleges; James Cosgrove, PhD, director of the U.S. Government Accountability Office; Otis W. Brawley, MD, chief medical officer of the American Cancer Society; and Peter Friedl, MD, PhD, of St. Radboud University Nijmegen Medical Centre at the University of Nijmegen and MD Anderson Cancer Center.
ASTRO is the premier radiation oncology society in the world, with more than 10,000 members who are physicians, nurses, biologists, physicists, radiation therapists, dosimetrists and other health care professionals that specialize in treating patients with radiation therapies. As the leading organization in radiation oncology, the Society is dedicated to improving patient care through professional education and training, support for clinical practice and health policy standards, advancement of science and research, and advocacy. ASTRO publishes two medical journals, International Journal of Radiation Oncology • Biology • Physics and Practical Radiation Oncology; developed and maintains an extensive patient website, http://www.rtanswers.org; and created the Radiation Oncology Institute, a non-profit foundation to support research and education efforts around the world that enhance and confirm the critical role of radiation therapy in improving cancer treatment. To learn more about ASTRO, visit http://www.astro.org.
ABOUT THE AMERICAN UROLOGICAL ASSOCIATION
Founded in 1902 and headquartered near Baltimore, Md., the American Urological Association is a leading advocate for the specialty of urology, and has more than 19,000 members throughout the world. The AUA is a premier urologic association, providing invaluable support to the urologic community as it pursues its mission of fostering the highest standards of urologic care through education, research and the formulation of health policy.
AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.